Comparative Pharmacology
Head-to-head clinical analysis: HEPATOLITE versus IOBENGUANE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPATOLITE versus IOBENGUANE I 123.
HEPATOLITE vs IOBENGUANE I-123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPATOLITE is a synthetic hepatocyte growth factor analog that binds to c-Met receptors on hepatocytes, activating MAPK/ERK and PI3K/Akt pathways, promoting hepatocyte proliferation and liver regeneration.
Iobenguane I-123 is a radiopharmaceutical analog of norepinephrine that is taken up by adrenergic neurons and neuroendocrine tumors via the norepinephrine transporter (NET). It localizes in tissues rich in sympathetic innervation and tumors expressing NET, enabling scintigraphic imaging.
Intravenous: 50 mg/kg (ideal body weight) over 60 minutes once daily. Oral: 1000 mg three times daily.
Intravenous administration of 5 mCi (185 MBq) as a single dose for imaging.
None Documented
None Documented
Terminal elimination half-life is 2.5–4 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 5-7 hours; clinically relevant for imaging timing (optimal scanning at 24 hours post-injection)
Primarily renal excretion (unchanged drug and major metabolite) accounting for ~70% of elimination; biliary/fecal excretion accounts for ~25%; remainder undergoes minor metabolic clearance.
Renal: 40-60% as unchanged iobenguane within 24 hours; biliary/fecal: minimal (<5%)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical